Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical and rare disease company with approved and investigational therapies targeting rare liver and neurodevelopmental conditions. The Mirum news feed on Stock Titan aggregates company announcements, press releases and corporate disclosures so readers can follow how its commercial portfolio and pipeline evolve over time.
Investors and followers of MIRM can review news about LIVMARLI (maralixibat), CHOLBAM (cholic acid) and CTEXLI (chenodiol), including regulatory updates, commercial milestones and clinical study developments. Coverage also includes updates on clinical-stage programs such as volixibat for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug for chronic hepatitis delta virus (HDV) in connection with the proposed Bluejay Therapeutics acquisition, and MRM-3379 for Fragile X syndrome (FXS).
News items commonly highlight Mirum’s participation in healthcare and investor conferences, private placement financings, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and material events reported via Form 8-K filings. Company press releases also discuss regulatory designations, study initiations, enrollment updates and planned timelines for key clinical readouts, as described in Mirum’s own communications.
This page offers a centralized view of Mirum-related headlines, allowing readers to track commercial performance commentary, pipeline progress and transaction announcements in one place. For users researching MIRM stock or the company’s rare disease programs, the news feed provides direct access to the narrative Mirum shares with the market.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported 2025 net product sales of $521.3M and provided 2026 guidance of $630M–$650M in expected global net product sales. The company highlighted multiple near‑term registrational readouts in 2026 and recent regulatory approvals and an acquisition expanding its HDV program.
Key near‑term catalysts include VISTAS topline in PSC (Q2 2026), LIVMARLI EXPAND topline (Q4 2026), and AZURE HDV readouts in H2 2026. Cash and investments were $391.4M at year‑end 2025.
Mirum Pharmaceuticals (Nasdaq: MIRM) will participate in multiple investor conferences in early March 2026, including TD Cowen (March 2), Citizens Life Sciences (March 10), Barclays Global Healthcare (March 10), and Leerink Partners (March 11).
Fireside chat times: March 2 at 1:10 p.m. ET, March 10 at 10:10 a.m. ET, and March 11 at 10:00 a.m. ET. The company said the sessions will be webcast live and available for replay in Mirum's Investors section.
Mirum Pharmaceuticals (Nasdaq: MIRM) will report fourth quarter and year‑end 2025 financial results on February 25, 2026. A conference call and webcast will follow to discuss results and recent corporate progress.
The live call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT; dial‑in and webcast replay details are provided for investors.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement equity awards granted on February 10, 2026 to 37 new employees under its 2020 Inducement Plan. Awards include 163,040 non-qualified stock options at an exercise price of $100.91, 219,090 RSUs, and 48,880 PSUs.
Options vest over four years, RSUs vest over three years, and PSUs vest March 15, 2028 and March 15, 2029 if specified net product sales targets for 2027 and 2028 are met and service conditions are satisfied.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced Health Canada authorization of the LIVMARLI tablet formulation for treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) who weigh 22 kg or more and can swallow tablets.
The tablet complements the existing 9.5 mg/mL oral solution previously authorized for patients aged 12 months and older, offering an additional dosing option to support adherence and continuity of care. Mirum also announced Health Canada authorization for LIVMARLI in progressive familial intrahepatic cholestasis (PFIC) earlier the same day, covering both 19 mg/mL solution and tablet formulations.
Mirum Pharmaceuticals (NASDAQ: MIRM) announced Health Canada authorization of LIVMARLI (maralixibat) for treatment of cholestatic pruritus in patients aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC).
Authorization covers a 19 mg/mL oral solution and a tablet formulation (for patients ≥22 kg) and is supported by Phase 3 MARCH data (93 patients; p<0.0001 versus placebo).
Mirum Pharmaceuticals (NASDAQ: MIRM) completed its acquisition of Bluejay Therapeutics, acquiring worldwide rights to brelovitug, a late‑stage monoclonal antibody for chronic hepatitis delta virus (HDV).
Brelovitug holds FDA Breakthrough Therapy and EMA PRIME designations and is in the global AZURE Phase 3 registrational program with topline data expected in 2H 2026. Mirum financed the deal via cash and stock consideration plus potential tiered sales‑based milestones and closed concurrent private placement financings raising approximately $268.5 million to support clinical development and commercial activities.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement grants made on January 9, 2026 to five new employees under its 2020 Inducement Plan. The Compensation Committee granted non-qualified stock options to purchase 4,900 shares and 6,500 restricted stock units (RSUs).
Each option has an exercise price of $86.57 per share (Mirum's closing price on January 9, 2026). Options vest over four years (25% at one year, then monthly over 36 months). RSUs vest over three years (33% on each anniversary). Grants are subject to the 2020 Inducement Plan and applicable award agreements and to continued service through vesting dates.
Mirum Pharmaceuticals (NASDAQ: MIRM) reported preliminary unaudited full-year 2025 results and 2026 outlook. 2025 net product sales were approximately $520 million, above the top of guidance. Management expects 2026 net product sales of $630M–$650M. 2025 LIVMARLI net sales were ~$359M (including ~$243M US), +69% YoY; CHOLBAM and CTEXLI combined ~$161M, +31% YoY. Year-end cash, cash equivalents and investments are expected to be ~$392M vs $292.8M a year earlier. Key upcoming catalysts: volixibat VISTAS PSC topline Q2 2026, LIVMARLI EXPAND topline Q4 2026, and proposed Bluejay acquisition with AZURE HDV data in H2 2026 (pending close).
Enthorin Therapeutics announced that licensing partner Mirum Pharmaceuticals (NASDAQ: MIRM) initiated the BLOOM Phase 2 clinical study of MRM-3379 (formerly ENT-3379) in Fragile X syndrome in December. MRM-3379 is described as an orally available, highly brain-penetrant, selective PDE4D inhibitor designed to enhance cAMP signaling. The compound was discovered at Dart Neuroscience and advanced through Phase 1; preclinical data in an FMR1 knockout mouse reportedly showed improved cognition and reduced behavioral deficits. Enthorin acknowledged the clinical and scientific teams involved in the decade-long research and development leading to this patient-trial milestone.